Drug–Drug Interactions with Sodium-Glucose Cotransporters Type 2 (SGLT2) Inhibitors, New Oral Glucose-Lowering Agents for the Management of Type 2 Diabetes Mellitus

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Clinical Pharmacokinetics

• Publication date

  2014-01-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s40262-013-0128-8PMID 24420910
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study.

  2015cited by this paper
• Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations

  2014influential reference
• Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor

  2014cited by this paper
• Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment

  2014cited by this paper
• Canagliflozin, an inhibitor of sodium–glucose cotransporter 2, for the treatment of type 2 diabetes mellitus

  2013influential reference
• Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin

  2013cited by this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-transporter Type 2

  2013influential reference
• Lack of drug–drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers

  2013cited by this paper
• Canagliflozin: First Global Approval

  2013cited by this paper
• Impact of Voglibose on the Pharmacokinetics of Dapagliflozin in Japanese Patients with Type 2 Diabetes

  2013cited by this paper
• Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

  2013cited by this paper
• Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2013cited by this paper
• Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteers.

  2013cited by this paper
• Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers.

  2013cited by this paper
• Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose‐Dependent Glucosuria in Healthy Subjects

  2013cited by this paper
• A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers.

  2013cited by this paper
• The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) in clinical practice in patients with vascular diseases or type 2 diabetes mellitus

  2013cited by this paper
• The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.

  2013cited by this paper
• Effect of Empagliflozin on the Steady-State Pharmacokinetics of Ethinylestradiol and Levonorgestrel in Healthy Female Volunteers

  2013cited by this paper
• Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease

  2013influential reference
• Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Sodium Glucose Co‐Transporter 2 Inhibitor, in Subjects With Type 2 Diabetes Mellitus

  2013cited by this paper
• Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2012cited by this paper
• Oral Antidiabetic Agents

  2012cited by this paper
• Drug-Drug Interactions with Glucagon-Like Peptide-1 Receptor Agonists

  2012cited by this paper
• Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors

  2012cited by this paper
• Pharmacokinetics of Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, and Glimepiride Following Co-administration in Healthy Volunteers: A Randomised, Open-label, Crossover Study

  2012cited by this paper
• Pharmacokinetics of Empagliflozin, a Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitor, Coadministered with Sitagliptin in Healthy Volunteers

  2012cited by this paper
• RECOMMANDATIONS 2012 EN DIABÉTOLOGIE: Prise en charge de l'hyperglycémie dans le diabète de type 2: une approche centrée sur le patient

  2012cited by this paper
• Dapagliflozin

  2012influential reference
• Lack of Pharmacokinetic Interactions Between Dapagliflozin and Simvastatin, Valsartan, Warfarin, or Digoxin

  2012influential reference
• Management of type 2 diabetes: new and future developments in treatment.

  2011cited by this paper
• Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations

  2011cited by this paper
• Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium–glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects

  2011cited by this paper
• Cytochrome P450-mediated cardiovascular drug interactions

  2011cited by this paper
• Erratum to: Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions

  2011cited by this paper
• Renal glucose reabsorption inhibitors to treat diabetes.

  2011cited by this paper
• Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.

  2011cited by this paper
• Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24‐week, double‐blind, placebo‐controlled trial

  2011cited by this paper
• Dipeptidylpeptidase-4 Inhibitors (Gliptins)

  2010cited by this paper
• Potential CYP2C9‐mediated drug–drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizide

  2010cited by this paper
• Drug-Drug and Food-Drug Pharmacokinetic Interactions with New Insulinotropic Agents Repaglinide and Nateglinide

  2007cited by this paper
• Pharmacokinetic Interactions with Thiazolidinediones

  2007cited by this paper
• Drug Interactions of Clinical Importance with Antihyperglycaemic Agents : An Update.

  2005cited by this paper
• Drug Interactions of Clinical Importance with Antihyperglycaemic Agents

  2005cited by this paper
• Onset Properties of Rocuronium during Co-Induction of Anaesthesia with Desflurane and Isoflurane or Total Intravenous Anaesthesia

  2000cited by this paper
• Oral Antidiabetic Agents

  1998cited by this paper
• Antihyperglycaemic Agents

  1995cited by this paper
• Reduction of the acute bioavailability of metformin by the α‐glucosidase inhibitor acarbose in normal man

  1994cited by this paper

• A Data Mining Approach on Polypharmacy and Drug-drug Interactions of Common Diabetes Medications.

  2025cites this paper
• An Insight Into Commercially Available SGLT2 Inhibitors and Their Structure–Activity Relationship Studies

  2025cites this paper
• SGLT2 inhibitors in type 2 diabetes mellitus: a pharmacist’s guide to optimised care

  2025cites this paper
• Potential Role of SGLT‐2 Inhibitors in Improving Allograft Function and Reducing Rejection in Kidney Transplantation

  2025cites this paper
• In vivo assessment of pharmacokinetic interactions of empagliflozin and henagliflozin with sorafenib: an animal-based study

  2025influential citation
• Advances in Cardiovascular Pharmacotherapy. IV. Sodium-Glucose Cotransporter Type 2 Inhibitors, Part 2: Mechanisms for Myocardial Protection, Adverse Effects, and Perioperative Implications.

  2025cites this paper
• Impact of sodium–glucose transport protein-2 (SGLT2) inhibitors on the inflammasome pathway in acute myocardial infarction in type 2 diabetes mellitus: a comprehensive review

  2025cites this paper
• Effects of SGLT2-inhibitor on The Expression of MicroRNA-21, Transforming Growth Factor-β1, and Matrix Metalloproteinase-2 in The Process of Cardiac Fibrosis in Hyperglycemic Model Rats

  2024cites this paper
• Real-world safety of dapagliflozin plus metformin in patients of type 2 diabetes mellitus in China: Post-hoc analysis of the DONATE study.

  2024cites this paper
• Update on Sodium Glucose Cotransporter Type 2 Inhibitors Use in Kidney Transplant Patients

  2024cites this paper
• Recent Progress and Perspectives in Sodium-Glucose Co-transporter 1/2 Inhibitors.

  2024cites this paper
• DAPAGLIFLOZIN: A NEW HOPE FOR THE THERAPEUTIC TREATMENT OF TYPE 2 DIABETES MELLITUS

  2024cites this paper
• Development of a highly sensitive and eco-friendly high-performance thin-layer chromatography approach for the determination of empagliflozin, pioglitazone, and rosuvastatin simultaneously in pharmaceutical preparations and different biological fluids

  2023cites this paper
• The Safety Profile of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists in the Standard of Care Treatment of Type 2 Diabetes Mellitus

  2023influential citation
• Systems Pharmacology and Network Analysis to Advance Pharmacogenomics and Precision Medicine Decisions in Type-2 Diabetes Therapy

  2023cites this paper
• Concomitant use of statins and sodium‐glucose co‐transporter 2 inhibitors and the risk of myotoxicity reporting: A disproportionality analysis

  2023cites this paper
• Synthesis, Isolation, Characterization and Suppression of Impurities during Optimization of Empagliflozin (Jardiance)

  2022cites this paper
• Glycaemic Control in Patients Undergoing Percutaneous Coronary Intervention: What Is the Role for the Novel Antidiabetic Agents? A Comprehensive Review of Basic Science and Clinical Data

  2022cites this paper
• Clinical conundrums involving statin drug-drug interactions.

  2022cites this paper
• Development of UPLC-MS/MS Method to Study the Pharmacokinetic Interaction between Sorafenib and Dapagliflozin in Rats

  2022cites this paper
• Counteracting heart failure with diabetes drugs: a review into the pharmacokinetic and pharmacodynamic properties

  2022cites this paper
• Drug–drug interaction potential and clinical pharmacokinetics of enerisant, a novel potent and selective histamine H3 receptor antagonist

  2021cites this paper
• Drug-drug Interactions between Hypoglycemic and Non-hypoglycemic Medication in Diabetic Patients with Comorbidities in a Tertiary Care Center: A Descriptive Cross-sectional Study

  2021cites this paper
• In vitro study of the drug–drug interaction potential of cetagliptin and clinical study of pharmacokinetic interaction of cetagliptin and metformin in healthy volunteers

  2021cites this paper
• Potential drug-drug interaction between sodium-glucose co-transporter 2 inhibitors and statins: pharmacological and clinical evidence

  2021cites this paper
• SGLT2 Inhibitors: A Noval Therapuetic Agent in the Treatment of Diabetic Kidney Disease

  2020cites this paper
• Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor

  2020cites this paper
• Evaluation of the clearance mechanism of non-CYP-mediated drug metabolism and DDI as a victim drug

  2020cites this paper
• Management of diabetes mellitus in patients undergoing liver transplantation

  2019cites this paper
• Hormonal, Metabolic and Hemodynamic Adaptations to Glycosuria in Type 2 Diabetes Patients Treated with Sodium-Glucose Co-Transporter Inhibitors.

  2019cites this paper
• An update on the safety of SGLT2 inhibitors

  2019cites this paper
• Liquid chromatography tandem mass spectrometry for the simultaneous determination of metformin and pioglitazone in rat plasma: Application to pharmacokinetic and drug-drug interaction studies.

  2019cites this paper
• New antihyperglycemic medications with cardiovascular protection for patients with diabetes: What do surgeons need to know?

  2019cites this paper
• Dapagliflozin : manfaat dan risiko pada diabetes melitus tipe 2

  2019cites this paper
• Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes

  2019influential citation
• Treatment with Oral Drugs

  2018cites this paper
• Inhibitory effects of sulfonylureas and non‐steroidal anti‐inflammatory drugs on in vitro metabolism of canagliflozin in human liver microsomes

  2018cites this paper
• Sodium-glucose Cotransporter-2 Inhibitors in Combination with Other Glucose-lowering Agents for the Treatment of Type 2 Diabetes Mellitus

  2018cites this paper
• Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes

  2017cites this paper
• Drug-drug interactions between immunosuppressants and antidiabetic drugs in the treatment of post-transplant diabetes mellitus.

  2017cites this paper
• Metabolomic analysis of antidiabetic drug action

  2017cites this paper
• In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor

  2017influential citation
• Pharmacokinetic drug evaluation of saxagliptin plus dapagliflozin for the treatment of type 2 diabetes

  2017cites this paper
• Sodium–glucose cotransporter 2 inhibitors for treating diabetes mellitus

  2017cites this paper
• Effects of SGLT2 inhibitors on weight loss in patients with type 2 diabetes mellitus.

  2017cites this paper
• Evaluation of Comparative Efficacy and Pleiotrophy of the Available Three SGLT2 Inhibitors in Type 2 DM Subjects

  2016cites this paper
• Benefits/Risks of Sodium–Glucose Co-Transporter 2 Inhibitor Canagliflozin in Women for the Treatment of Type 2 Diabetes

  2016cites this paper
• I nuovi farmaci per il diabete: gli inibitori del co-trasportatore sodio-glucosio di tipo 2 (SGLT-2i)

  2016cites this paper
• Evaluation of drug–drug interaction between henagliflozin, a novel sodium-glucose co-transporter 2 inhibitor, and metformin in healthy Chinese males

  2016cites this paper
• SGLT2 Inhibitors: Benefit/Risk Balance

  2016cites this paper
• Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus

  2016cites this paper
• The Novel Role of the Kidney in Diabetes Management: Sodium-Glucose Co-Transporter 2 Inhibitors

  2015cites this paper
• Pharmacokinetics, pharmacodynamics and clinical efficacy of dapagliflozin for the treatment of type 2 diabetes

  2015cites this paper
• Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease

  2015cites this paper
• Ipragliflozin, a sodium–glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes

  2015cites this paper
• Preclinical metabolism and disposition of luseogliflozin, a novel antihyperglycemic agent

  2015influential citation
• The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes.

  2015cites this paper
• Absence of Drug–Drug Interactions Between Luseogliflozin, a Sodium–Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males

  2015cites this paper
• SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment

  2015cites this paper
• Sodium glucose cotransporter 2 inhibitors.

  2015cites this paper
• Clinical Pharmacokinetic, Pharmacodynamic, and Drug–Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor

  2015influential citation
• A simple and sensitive high performance liquid chromatography assay with a fluorescence detector for determination of canagliflozin in human plasma

  2015cites this paper
• Pharmacogenetics: Implications for Modern Type 2 Diabetes Therapy.

  2015cites this paper
• Empagliflozin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus

  2014influential citation
• Canagliflozin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus

  2014cites this paper
• Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus

  2014cites this paper
• Clinical Pharmacokinetics and Pharmacodynamics of the Novel SGLT2 Inhibitor Ipragliflozin

  2014cites this paper
• Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors—Fighting Diabetes from a New Perspective

  2014cites this paper
• Pharmacokinetic drug interactions are unlikely when sodium–glucose cotransporters type 2 inhibitors are used to treat type 2 diabetes mellitus

  2014influential citation
• Inhibitory sodozależnego kotransportera 2 glukozy — nowa grupa leków w leczeniu cukrzycy

  2014cites this paper
• Pharmacokinetic drug interactions are unlikely when sodium–glucose cotransporters type 2 inhibitors are used to treat type 2 diabetes mellitus

  2014cites this paper
• Gliflozins or SGLT2 Inhibitors: Still More Questions To Be Answered

  2014cites this paper
• A safety evaluation of canagliflozin: a first-in-class treatment for type 2 diabetes

  2014cites this paper
• Dapagliflozin: A Review of Its Use in Patients with Type 2 Diabetes

  2014cites this paper